New Paradigms to Assess Consequences of Long-Term, Low-Dose Curcumin Exposure in Lung Cancer Cells.
Animals
Antineoplastic Agents, Phytogenic
/ administration & dosage
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Curcumin
/ administration & dosage
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
/ drug effects
Fibroblasts
Humans
Immunohistochemistry
Mice
Time Factors
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
chemotherapy
curcumin
lung cancer
resistance
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
16 Jan 2020
16 Jan 2020
Historique:
received:
01
10
2019
revised:
13
01
2020
accepted:
14
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Curcumin has been investigated extensively for cancer prevention, but it has been proposed that long-term treatments may promote clonal evolution and gain of cellular resistance, potentially rendering cancer cells less sensitive to future therapeutic interventions. Here, we used long-term, low-dose treatments to determine the potential for adverse effects in non-small cell lung cancer (NSCLC) cells. IC
Identifiants
pubmed: 31963196
pii: molecules25020366
doi: 10.3390/molecules25020366
pmc: PMC7024150
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK
ID : 13101
Pays : United Kingdom
Organisme : Indena SPA
ID : LH01
Organisme : Cancer Research UK
ID : [C10604/A25151].
Pays : United Kingdom
Références
Free Radic Biol Med. 2009 Jan 15;46(2):299-304
pubmed: 19026740
Expert Opin Ther Targets. 2012 Jun;16(6):553-72
pubmed: 22530990
Nicotine Tob Res. 2019 Jul 17;21(8):1045-1050
pubmed: 29889248
Cancer Treat Rev. 2017 Nov;60:1-11
pubmed: 28843992
Mol Ther Oncolytics. 2016 Aug 03;3:16018
pubmed: 27525306
Pathol Int. 2019 Aug;69(8):472-480
pubmed: 31339210
Phytomedicine. 2019 May;58:152740
pubmed: 31005718
Respir Res. 2017 Jun 15;18(1):118
pubmed: 28619066
Sci Rep. 2016 Apr 19;6:24675
pubmed: 27091625
Oncotarget. 2017 Nov 21;8(65):108498-108508
pubmed: 29312546
Orthop Surg. 2019 Feb;11(1):117-125
pubmed: 30560591
Clin Cancer Res. 2009 Nov 1;15(21):6630-8
pubmed: 19843665
Int J Cancer. 2016 Jan 1;138(1):30-44
pubmed: 25611701
Carcinogenesis. 2014 May;35(5):974-82
pubmed: 24618374
J Pharmacol Exp Ther. 2014 Sep;350(3):483-94
pubmed: 24939419
Tumour Biol. 2015 May;36(5):3591-9
pubmed: 25542235
Steroids. 2014 Nov;90:44-52
pubmed: 24930824
Clin Cancer Res. 2016 Aug 15;22(16):4005-13
pubmed: 27370607
Ann Transl Med. 2017 Jan;5(1):2
pubmed: 28164087
Sci Rep. 2019 Jan 24;9(1):491
pubmed: 30679571
Nutr Cancer. 2010;62(7):919-30
pubmed: 20924967
Cancer Prev Res (Phila). 2013 Feb;6(2):119-28
pubmed: 23233733
Ann Oncol. 2015 Oct;26(10):2066-72
pubmed: 26153496
Cell Mol Neurobiol. 2012 Aug;32(6):1003-10
pubmed: 22410671
Cell Mol Biol Lett. 2019 May 22;24:32
pubmed: 31143210
Chem Biol Drug Des. 2011 Jun;77(6):494-9
pubmed: 21332948
J Nat Prod. 2011 Apr 25;74(4):664-9
pubmed: 21413691
N Engl J Med. 1996 May 2;334(18):1150-5
pubmed: 8602180
Molecules. 2019 Jul 10;24(14):
pubmed: 31295906
Eur J Cancer Prev. 2007 Jun;16(3):184-91
pubmed: 17415088
Mol Nutr Food Res. 2016 Jun;60(6):1437-47
pubmed: 26603273
PLoS One. 2018 Nov 15;13(11):e0207405
pubmed: 30440021
J Breast Cancer. 2019 Jun 07;22(2):237-247
pubmed: 31281726
Inflammation. 2019 Aug;42(4):1441-1455
pubmed: 31028577
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Clin Nutr. 1995 Dec;62(6 Suppl):1427S-1430S
pubmed: 7495243
Cancer. 2017 Aug 1;123(15):2936-2944
pubmed: 28472537
Int J Cancer. 2011 Jul 15;129(2):476-86
pubmed: 20839263